αv-Integrin isoform expression in primary human tumors and brain metastases

International Journal of Cancer

Volumn 133, Issue 10, 2013, Pages 2362-2371

  Vogetseder, Alexander ^a   Thies, Svenja ^a   Ingold, Barbara ^a   Roth, Patrick ^b   Weller, Michael ^b   Schraml, Peter ^a   Goodman, Simon L ^c   Moch, Holger ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^c MERCK KGAA   (Germany)

Author keywords

brain metastases; cilengitide; integrin

Indexed keywords

ALPHAVBETA5 INTEGRIN; ALPHAVBETA6 INTEGRIN; ALPHAVBETA8 INTEGRIN; CD51 ANTIGEN; MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG; VITRONECTIN RECEPTOR; CILENGITIDE;

ANTIBODY SPECIFICITY; ARTICLE; BRAIN METASTASIS; BREAST ADENOCARCINOMA; CONTROLLED STUDY; CUTANEOUS MELANOMA; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; KIDNEY CARCINOMA; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; PRIMARY TUMOR; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; ANTIGEN EXPRESSION; BREAST CANCER; BREAST METASTASIS; CARCINOGENESIS; CELL ADHESION; CELL MOTILITY; ENDOTHELIUM CELL; GLIOBLASTOMA; IMMUNOHISTOCHEMISTRY; KIDNEY CANCER; LUNG CANCER; LUNG CARCINOMA; MALIGNANT NEOPLASTIC DISEASE; MELANOMA; METASTATIC MELANOMA; NON SMALL CELL LUNG CANCER; PHASE 3 CLINICAL TRIAL; RENAL CLEAR CELL CANCER; STAINING; STROMA CELL; TISSUE MICROARRAY; TREND STUDY; TUMOR INVASION;

BRAIN METASTASES; CILENGITIDE; INTEGRIN;

BRAIN NEOPLASMS; BREAST NEOPLASMS; FEMALE; HUMANS; INTEGRIN ALPHAV; KIDNEY NEOPLASMS; LUNG NEOPLASMS; MELANOMA; NEOPLASM METASTASIS; NEOPLASMS; PROTEIN ISOFORMS;

EID: 84883751391     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28267     Document Type: Article

References (48)

1. Santarelli JG, Sarkissian V, Hou LC, et al. Molecular events of brain metastasis. Neurosurg Focus 2007; 22: E1.
2. Stetler-Stevenson WG, Aznavoorian S, Liotta LA,. Tumor cell interactions with the extracellular matrix during invasion and metastasis. Annu Rev Cell Biol 1993; 9: 541-73.
3. Lorger M, Krueger JS, O'Neal M, et al. Activation of tumor cell integrin alphavbeta3 controls angiogenesis and metastatic growth in the brain. Proc Natl Acad Sci USA 2009; 106: 10666-71.
4. Guo W, Giancotti FG,. Integrin signalling during tumour progression. Nat Rev Mol Cell Biol 2004; 5: 816-26.
5. Hynes RO,. Integrins: bidirectional, allosteric signaling machines. Cell 2002; 110: 673-87.
6. Hehlgans S, Haase M, Cordes N,. Signalling via integrins: implications for cell survival and anticancer strategies. Biochim Biophys Acta 2007; 1775: 163-80.
7. Desgrosellier JS, Cheresh DA,. Integrins in cancer: biological implications and therapeutic opportunities. Nat Rev Cancer 2010; 10: 9-22.
8. Felding-Habermann B,. Integrin adhesion receptors in tumor metastasis. Clin Exp Metastasis 2003; 20: 203-13.
9. Stupack DG, Cheresh DA,. Get a ligand, get a life: integrins, signaling and cell survival. J Cell Sci 2002; 115: 3729-38.
10. Zutter MM,. Integrin-mediated adhesion: tipping the balance between chemosensitivity and chemoresistance. Adv Exp Med Biol 2007; 608: 87-100.
11. Ricono JM, Huang M, Barnes LA, et al. Specific cross-talk between epidermal growth factor receptor and integrin alphavbeta5 promotes carcinoma cell invasion and metastasis. Cancer Res 2009; 69: 1383-91.
12. Matsuo M, Sakurai H, Ueno Y, et al. Activation of MEK/ERK and PI3K/Akt pathways by fibronectin requires integrin alphav-mediated ADAM activity in hepatocellular carcinoma: a novel functional target for gefitinib. Cancer Sci 2006; 97: 155-62.
13. Pouliot N, Connolly LM, Moritz RL, et al. Colon cancer cells adhesion and spreading on autocrine laminin-10 is mediated by multiple integrin receptors and modulated by EGF receptor stimulation. Exp Cell Res 2000; 261: 360-71.
14. Somanath PR, Malinin NL, Byzova TV,. Cooperation between integrin alphavbeta3 and VEGFR2 in angiogenesis. Angiogenesis 2009; 12: 177-85.
15. Schneller M, Vuori K, Ruoslahti E,. Alphavbeta3 integrin associates with activated insulin and PDGFbeta receptors and potentiates the biological activity of PDGF. EMBO J 1997; 16: 5600-7.
16. Barbolina MV, Kim M, Liu Y, et al. Microenvironmental regulation of chemokine (C-X-C-motif) receptor 4 in ovarian carcinoma. Mol Cancer Res 2010; 8: 653-64.
17. Albelda SM, Mette SA, Elder DE, et al. Integrin distribution in malignant melanoma: association of the beta 3 subunit with tumor progression. Cancer Res 1990; 50: 6757-64.
18. Felding-Habermann B, Mueller BM, Romerdahl CA, et al. Involvement of integrin alpha V gene expression in human melanoma tumorigenicity. J Clin Invest 1992; 89: 2018-22.
19. Felding-Habermann B, O'Toole TE, Smith JW, et al. Integrin activation controls metastasis in human breast cancer. Proc Natl Acad Sci USA 2001; 98: 1853-8.
20. Mitjans F, Sander D, Adan J, et al. An anti-alpha v-integrin antibody that blocks integrin function inhibits the development of a human melanoma in nude mice. J Cell Sci 1995; 108: 2825-38.
21. Liapis H, Flath A, Kitazawa S,. Integrin alpha V beta 3 expression by bone-residing breast cancer metastases. Diagn Mol Pathol 1996; 5: 127-35.
22. Kawashima A, Tsugawa S, Boku A, et al. Expression of alphav integrin family in gastric carcinomas: increased alphavbeta6 is associated with lymph node metastasis. Pathol Res Pract 2003; 199: 57-64.
23. Friedlander M, Brooks PC, Shaffer RW, et al. Definition of two angiogenic pathways by distinct alpha v integrins. Science 1995; 270: 1500-2.
24. Buerkle MA, Pahernik SA, Sutter A, et al. Inhibition of the alpha-nu integrins with a cyclic RGD peptide impairs angiogenesis, growth and metastasis of solid tumours in vivo. Br J Cancer 2002; 86: 788-95.
25. Brooks PC, Stromblad S, Klemke R, et al. Antiintegrin alpha v beta 3 blocks human breast cancer growth and angiogenesis in human skin. J Clin Invest 1995; 96: 1815-22.
26. Goodman SL, Picard M,. Integrins as therapeutic targets. Trends Pharmacol Sci 2012; 33: 405-12.
27. Dechantsreiter MA, Planker E, Matha B, et al. N-methylated cyclic RGD peptides as highly active and selective alpha(V)beta(3) integrin antagonists. J Med Chem 1999; 42: 3033-40.
28. Nisato RE, Tille JC, Jonczyk A, et al. alphav beta 3 and alphav beta 5 integrin antagonists inhibit angiogenesis in vitro. Angiogenesis 2003; 6: 105-19.
29. MacDonald TJ, Taga T, Shimada H, et al. Preferential susceptibility of brain tumors to the antiangiogenic effects of an alpha(v) integrin antagonist. Neurosurgery 2001; 48: 151-7.
30. Mikkelsen T, Brodie C, Finniss S, et al. Radiation sensitization of glioblastoma by cilengitide has unanticipated schedule-dependency. Int J Cancer 2009; 124: 2719-27.
31. Goodman SL, Grote HJ, Wilm C,. Matched rabbit monoclonal antibodies against alphav-series integrins reveal a novel alphavbeta3-LIBS epitope, and permit routine staining of archival paraffin samples of human tumors. Biol Open 2012; 1: 329-40.
32. Prudkin L, Liu DD, Ozburn NC, et al. Epithelial-to-mesenchymal transition in the development and progression of adenocarcinoma and squamous cell carcinoma of the lung. Mod Pathol 2009; 22: 668-78.
33. Monnier Y, Farmer P, Bieler G, et al. CYR61 and alphaVbeta5 integrin cooperate to promote invasion and metastasis of tumors growing in preirradiated stroma. Cancer Res 2008; 68: 7323-31.
34. Cowden Dahl KD, Robertson SE, Weaver VM, et al. Hypoxia-inducible factor regulates alphavbeta3 integrin cell surface expression. Mol Biol Cell 2005; 16: 1901-12.
35. Tchaicha JH, Mobley AK, Hossain MG, et al. A mosaic mouse model of astrocytoma identifies alphavbeta8 integrin as a negative regulator of tumor angiogenesis. Oncogene 2010; 29: 4460-72.
36. Arnold TD, Ferrero GM, Qiu H, et al. Defective retinal vascular endothelial cell development as a consequence of impaired integrin alphaVbeta8-mediated activation of transforming growth factor-beta. J Neurosci 2012; 32: 1197-206.
37. Mu D, Cambier S, Fjellbirkeland L, et al. The integrin alpha(v)beta8 mediates epithelial homeostasis through MT1-MMP-dependent activation of TGF-beta1. J Cell Biol 2002; 157: 493-507.
38. Pozzi A, Zent R,. TGF-beta sequestration by mesangial cell integrin alphavbeta8: a novel mechanism of glomerular endothelial cell regulation. Am J Pathol 2011; 178: 485-9.
39. Proctor JM, Zang K, Wang D, et al. Vascular development of the brain requires beta8 integrin expression in the neuroepithelium. J Neurosci 2005; 25: 9940-8.
40. Bandyopadhyay A, Raghavan S,. Defining the role of integrin alphavbeta6 in cancer. Curr Drug Targets 2009; 10: 645-52.
41. Beer AJ, Niemeyer M, Carlsen J, et al. Patterns of alphavbeta3 expression in primary and metastatic human breast cancer as shown by 18F-Galacto-RGD PET. J Nucl Med 2008; 49: 255-9.
42. Sloan EK, Pouliot N, Stanley KL, et al. Tumor-specific expression of alphavbeta3 integrin promotes spontaneous metastasis of breast cancer to bone. Breast Cancer Res 2006; 8: R20.
43. Huang X, Griffiths M, Wu J, et al. Normal development, wound healing, and adenovirus susceptibility in beta5-deficient mice. Mol Cell Biol 2000; 20: 755-9.
44. Reynolds LE, Wyder L, Lively JC, et al. Enhanced pathological angiogenesis in mice lacking beta3 integrin or beta3 and beta5 integrins. Nat Med 2002; 8: 27-34.
45. Mas-Moruno C, Rechenmacher F, Kessler H,. Cilengitide: the first anti-angiogenic small molecule drug candidate design, synthesis and clinical evaluation. Anticancer Agents Med Chem 2010; 10: 753-68.
46. Lomonaco SL, Finniss S, Xiang C, et al. Cilengitide induces autophagy-mediated cell death in glioma cells. Neuro Oncol 2011; 13: 857-65.
47. Taga T, Suzuki A, Gonzalez-Gomez I, et al. alpha v-Integrin antagonist EMD 121974 induces apoptosis in brain tumor cells growing on vitronectin and tenascin. Int J Cancer 2002; 98: 690-7.
48. Maurer GD, Tritschler I, Adams B, et al. Cilengitide modulates attachment and viability of human glioma cells, but not sensitivity to irradiation or temozolomide in vitro. Neuro Oncol 2009; 11: 747-56.